Answers are grounded in this paper and cite their sources.
Systematic review shows nirmatrelvir/ritonavir may reduce long COVID risk in outpatients, indicating varying symptom benefits.
Early outpatient treatment with nirmatrelvir/ritonavir may mitigate the risk of developing several domains of long COVID, though its benefits are not uniform across all symptom categories.
No takes yet. Share an insight, caveat, or question.
Cucunawangsih et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: